Debiopharm’s new Debio 1454 is the company’s second project to be awarded CARB-X support

(BOSTON, USA) – CARB-X is awarding Debiopharm International SA of Lausanne, Switzerland, up to $2.1 million in non-dilutive funding with the possibility of $1.6 million more if certain project milestones are met, to advance the development of a new class of antibiotics that inhibit bacterial fatty acid biosynthesis, an essential pathway in many drug-resistant bacterial species.  This new class of antibiotics is in development for the treatment of hospital-acquired pneumonia caused by the multidrug-resistant superbug Acinetobacter baumannii.

“The world urgently needs new approaches, new classes of antibiotics and rapid diagnostics to treat infections caused by drug-resistant bacteria. Debiopharm’s Debio 1454 project represents an exciting new class of antibiotics, that if successful and approved for use in patients, could save lives and be a huge step forward in the global fight against drug resistance,” said Kevin Outterson Executive Director of CARB-X and professor of law at Boston University. “We are making solid progress in supporting antibacterial innovation, but we know that much more is needed. It will take increased investment and concerted global leadership to deliver the antibiotics and other life-saving products we need to address the superbug crisis.”

Read more…